{
    "nct_id": "NCT05197257",
    "official_title": "68Ga-PSMA-11 PET in Patients With Prostate Cancer",
    "inclusion_criteria": "* Histopathologically proven prostate adenocarcinoma\n* Age â‰¥ 18 years\n* Patients already diagnosed with prostate cancer: Primary Staging: intermediate and high-risk patients per NCCN guidelines\n* Biochemical Recurrence: Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy):\n\n  a. Post radical prostatectomy (RP) - AUA recommendation i. PSA greater than or equal to 0.2 ng/mL measured more than 6-13 weeks after RP and confirmed by a second determination of a PSA level of >0.2 ng/mL b. Post-radiation therapy - ASTRO-Phoenix consensus definition i. Nadir + greater than or equal to 2 ng/mL rise in PSA\n* Ability to understand a written informed consent document, and the willingness to sign it.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Unable to lie flat, still or tolerate a PET/CT scan, or any other condition that would preclude PET/CT imaging.\n* Patients with any medical condition or circumstance that the investigator believes may compromise the data collection or lead to a failure to fulfil the study requirements.\n* Patients with known hypersensitivity to the active substance or to any of the excipients of the investigational product.",
    "miscellaneous_criteria": ""
}